呼吸器感染症再発治療薬の世界市場成長 2024-2030Global Medication for Recurrent Respiratory Infections Market Growth 2024-2030 小児の再発性呼吸器感染症は、小児によく見られる呼吸器疾患であり、1年間に6回以上の上気道感染症、または9月から4月までの1ヶ月間に1回以上の上気道感染症、または1年間に3回以上の下気道感染症を指す。 呼吸... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー小児の再発性呼吸器感染症は、小児によく見られる呼吸器疾患であり、1年間に6回以上の上気道感染症、または9月から4月までの1ヶ月間に1回以上の上気道感染症、または1年間に3回以上の下気道感染症を指す。呼吸器感染症再発治療薬の世界市場規模は、2024年の100万米ドルから2030年には100万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は%であると予測されている。 LPインフォメーション株式会社(東京都千代田区/代表取締役:劉克振、以下LPI)の最新調査レポート「呼吸器感染症再発治療薬産業予測」は、2023年の呼吸器感染症再発治療薬の世界総売上高を調査し、2024年から2030年までの呼吸器感染症再発治療薬の予測売上高を地域別・市場分野別に包括的に分析しています。呼吸器感染症再発治療薬の売上高を地域別、市場分野別、サブセクター別に分類し、世界の呼吸器感染症再発治療薬産業の詳細な分析を百万米ドル単位で提供します。 このインサイトレポートでは、世界の呼吸器感染症再発治療薬業界を包括的に分析し、製品区分、企業設立、収益、市場シェア、最新動向、M&A活動に関する主要動向を明らかにします。また、本レポートでは、呼吸器感染症再発治療薬のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、世界の主要企業の戦略を分析し、加速する呼吸器感染症再発治療薬世界市場におけるこれらの企業の独自の地位をより深く理解しています。 本インサイトレポートでは、呼吸器感染症再発治療薬の世界的な見通しを形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に分類して予測を行い、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の呼吸器感染症再発治療薬の現状と将来の軌道について非常にニュアンスのある見解を提供します。 呼吸器感染症再発治療薬の米国市場は、2023年の100万米ドルから2030年までに100万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。 呼吸器感染症再発治療薬の中国市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は%と推定される。 呼吸器感染症再発治療薬のヨーロッパ市場は、2023年の百万米ドルから2030年には百万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。 呼吸器感染症再発治療薬の世界的な主要企業は、Roche、Anko Bio、Bayer、Merck & Co、Sangeneなどである。売上高では、世界の2大企業が2023年にほぼ%のシェアを占めている。 のシェアを占めている。 当レポートでは、呼吸器感染症再発治療薬市場の包括的な概要、市場シェア、成長機会を、製品タイプ、用途、主要メーカー、主要地域、国別に紹介しています。 タイプ別セグメンテーション 免疫系製品 化学合成剤 生物学的製剤 その他 用途別セグメント 病院 クリニック その他 本レポートはまた、市場を地域別に分けています: 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、主要な専門家から収集した情報、および企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 ロシュ アンコ・バイオ バイエル メルク・アンド・カンパニー サンゲン カイン・テクノロジー シノバック製薬 ノバルティス バイオジェン メルクKGaA ザイダス・カディラ 華信バイオ ハルビン製薬グループ 厦門手宝 アドバケアファーマ コノテヘルスケア グラウダーマラボ ヤンセンファーマシューティカルズ 本レポートで扱う主な質問 世界の呼吸器感染症再発治療薬市場の10年見通しは? 世界および地域別で、呼吸器感染症治療薬市場の成長を促進する要因は何か? 市場別・地域別に最も急成長する技術は何か? 再発性呼吸器感染症治療薬の市場機会は最終市場規模によってどのように異なるのか? 呼吸器感染症再発治療薬のタイプ別、用途別内訳は? 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Medication for Recurrent Respiratory Infections Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Medication for Recurrent Respiratory Infections by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Medication for Recurrent Respiratory Infections by Country/Region, 2019, 2023 & 2030 2.2 Medication for Recurrent Respiratory Infections Segment by Type 2.2.1 Immune System Products 2.2.2 Chemical Synthetic Agents 2.2.3 Biological Agents 2.2.4 Other 2.3 Medication for Recurrent Respiratory Infections Sales by Type 2.3.1 Global Medication for Recurrent Respiratory Infections Sales Market Share by Type (2019-2024) 2.3.2 Global Medication for Recurrent Respiratory Infections Revenue and Market Share by Type (2019-2024) 2.3.3 Global Medication for Recurrent Respiratory Infections Sale Price by Type (2019-2024) 2.4 Medication for Recurrent Respiratory Infections Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Other 2.5 Medication for Recurrent Respiratory Infections Sales by Application 2.5.1 Global Medication for Recurrent Respiratory Infections Sale Market Share by Application (2019-2024) 2.5.2 Global Medication for Recurrent Respiratory Infections Revenue and Market Share by Application (2019-2024) 2.5.3 Global Medication for Recurrent Respiratory Infections Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Medication for Recurrent Respiratory Infections Breakdown Data by Company 3.1.1 Global Medication for Recurrent Respiratory Infections Annual Sales by Company (2019-2024) 3.1.2 Global Medication for Recurrent Respiratory Infections Sales Market Share by Company (2019-2024) 3.2 Global Medication for Recurrent Respiratory Infections Annual Revenue by Company (2019-2024) 3.2.1 Global Medication for Recurrent Respiratory Infections Revenue by Company (2019-2024) 3.2.2 Global Medication for Recurrent Respiratory Infections Revenue Market Share by Company (2019-2024) 3.3 Global Medication for Recurrent Respiratory Infections Sale Price by Company 3.4 Key Manufacturers Medication for Recurrent Respiratory Infections Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Medication for Recurrent Respiratory Infections Product Location Distribution 3.4.2 Players Medication for Recurrent Respiratory Infections Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Medication for Recurrent Respiratory Infections by Geographic Region 4.1 World Historic Medication for Recurrent Respiratory Infections Market Size by Geographic Region (2019-2024) 4.1.1 Global Medication for Recurrent Respiratory Infections Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Medication for Recurrent Respiratory Infections Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Medication for Recurrent Respiratory Infections Market Size by Country/Region (2019-2024) 4.2.1 Global Medication for Recurrent Respiratory Infections Annual Sales by Country/Region (2019-2024) 4.2.2 Global Medication for Recurrent Respiratory Infections Annual Revenue by Country/Region (2019-2024) 4.3 Americas Medication for Recurrent Respiratory Infections Sales Growth 4.4 APAC Medication for Recurrent Respiratory Infections Sales Growth 4.5 Europe Medication for Recurrent Respiratory Infections Sales Growth 4.6 Middle East & Africa Medication for Recurrent Respiratory Infections Sales Growth 5 Americas 5.1 Americas Medication for Recurrent Respiratory Infections Sales by Country 5.1.1 Americas Medication for Recurrent Respiratory Infections Sales by Country (2019-2024) 5.1.2 Americas Medication for Recurrent Respiratory Infections Revenue by Country (2019-2024) 5.2 Americas Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 5.3 Americas Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Medication for Recurrent Respiratory Infections Sales by Region 6.1.1 APAC Medication for Recurrent Respiratory Infections Sales by Region (2019-2024) 6.1.2 APAC Medication for Recurrent Respiratory Infections Revenue by Region (2019-2024) 6.2 APAC Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 6.3 APAC Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Medication for Recurrent Respiratory Infections by Country 7.1.1 Europe Medication for Recurrent Respiratory Infections Sales by Country (2019-2024) 7.1.2 Europe Medication for Recurrent Respiratory Infections Revenue by Country (2019-2024) 7.2 Europe Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 7.3 Europe Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Medication for Recurrent Respiratory Infections by Country 8.1.1 Middle East & Africa Medication for Recurrent Respiratory Infections Sales by Country (2019-2024) 8.1.2 Middle East & Africa Medication for Recurrent Respiratory Infections Revenue by Country (2019-2024) 8.2 Middle East & Africa Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 8.3 Middle East & Africa Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Medication for Recurrent Respiratory Infections 10.3 Manufacturing Process Analysis of Medication for Recurrent Respiratory Infections 10.4 Industry Chain Structure of Medication for Recurrent Respiratory Infections 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Medication for Recurrent Respiratory Infections Distributors 11.3 Medication for Recurrent Respiratory Infections Customer 12 World Forecast Review for Medication for Recurrent Respiratory Infections by Geographic Region 12.1 Global Medication for Recurrent Respiratory Infections Market Size Forecast by Region 12.1.1 Global Medication for Recurrent Respiratory Infections Forecast by Region (2025-2030) 12.1.2 Global Medication for Recurrent Respiratory Infections Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Medication for Recurrent Respiratory Infections Forecast by Type (2025-2030) 12.7 Global Medication for Recurrent Respiratory Infections Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 Roche 13.1.1 Roche Company Information 13.1.2 Roche Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.1.3 Roche Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Roche Main Business Overview 13.1.5 Roche Latest Developments 13.2 Anko Bio 13.2.1 Anko Bio Company Information 13.2.2 Anko Bio Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.2.3 Anko Bio Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Anko Bio Main Business Overview 13.2.5 Anko Bio Latest Developments 13.3 Bayer 13.3.1 Bayer Company Information 13.3.2 Bayer Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.3.3 Bayer Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Bayer Main Business Overview 13.3.5 Bayer Latest Developments 13.4 Merck & Co 13.4.1 Merck & Co Company Information 13.4.2 Merck & Co Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.4.3 Merck & Co Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Merck & Co Main Business Overview 13.4.5 Merck & Co Latest Developments 13.5 Sangene 13.5.1 Sangene Company Information 13.5.2 Sangene Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.5.3 Sangene Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Sangene Main Business Overview 13.5.5 Sangene Latest Developments 13.6 Kain Technology 13.6.1 Kain Technology Company Information 13.6.2 Kain Technology Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.6.3 Kain Technology Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Kain Technology Main Business Overview 13.6.5 Kain Technology Latest Developments 13.7 Sinovac Pharmaceuticals 13.7.1 Sinovac Pharmaceuticals Company Information 13.7.2 Sinovac Pharmaceuticals Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.7.3 Sinovac Pharmaceuticals Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Sinovac Pharmaceuticals Main Business Overview 13.7.5 Sinovac Pharmaceuticals Latest Developments 13.8 Novartis 13.8.1 Novartis Company Information 13.8.2 Novartis Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.8.3 Novartis Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Novartis Main Business Overview 13.8.5 Novartis Latest Developments 13.9 Biogen 13.9.1 Biogen Company Information 13.9.2 Biogen Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.9.3 Biogen Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Biogen Main Business Overview 13.9.5 Biogen Latest Developments 13.10 Merck KGaA 13.10.1 Merck KGaA Company Information 13.10.2 Merck KGaA Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.10.3 Merck KGaA Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Merck KGaA Main Business Overview 13.10.5 Merck KGaA Latest Developments 13.11 Zydus Cadila 13.11.1 Zydus Cadila Company Information 13.11.2 Zydus Cadila Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.11.3 Zydus Cadila Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Zydus Cadila Main Business Overview 13.11.5 Zydus Cadila Latest Developments 13.12 Huaxin Bio 13.12.1 Huaxin Bio Company Information 13.12.2 Huaxin Bio Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.12.3 Huaxin Bio Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 Huaxin Bio Main Business Overview 13.12.5 Huaxin Bio Latest Developments 13.13 Harbin Pharmaceutical Group 13.13.1 Harbin Pharmaceutical Group Company Information 13.13.2 Harbin Pharmaceutical Group Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.13.3 Harbin Pharmaceutical Group Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 Harbin Pharmaceutical Group Main Business Overview 13.13.5 Harbin Pharmaceutical Group Latest Developments 13.14 Xiamen Tebao 13.14.1 Xiamen Tebao Company Information 13.14.2 Xiamen Tebao Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.14.3 Xiamen Tebao Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 Xiamen Tebao Main Business Overview 13.14.5 Xiamen Tebao Latest Developments 13.15 AdvaCare Pharma 13.15.1 AdvaCare Pharma Company Information 13.15.2 AdvaCare Pharma Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.15.3 AdvaCare Pharma Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 AdvaCare Pharma Main Business Overview 13.15.5 AdvaCare Pharma Latest Developments 13.16 Connote Healthcare 13.16.1 Connote Healthcare Company Information 13.16.2 Connote Healthcare Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.16.3 Connote Healthcare Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Connote Healthcare Main Business Overview 13.16.5 Connote Healthcare Latest Developments 13.17 Glowderma Lab 13.17.1 Glowderma Lab Company Information 13.17.2 Glowderma Lab Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.17.3 Glowderma Lab Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Glowderma Lab Main Business Overview 13.17.5 Glowderma Lab Latest Developments 13.18 Janssen Pharmaceuticals 13.18.1 Janssen Pharmaceuticals Company Information 13.18.2 Janssen Pharmaceuticals Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.18.3 Janssen Pharmaceuticals Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Janssen Pharmaceuticals Main Business Overview 13.18.5 Janssen Pharmaceuticals Latest Developments 14 Research Findings and Conclusion
SummaryRecurrent respiratory tract infections in children are common respiratory diseases in children, referring to more than 6 upper respiratory tract infections in a year, or more than 1 upper respiratory tract infection per month between September and April, or more than 3 lower respiratory tract infections in a year. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Medication for Recurrent Respiratory Infections Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Medication for Recurrent Respiratory Infections by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Medication for Recurrent Respiratory Infections by Country/Region, 2019, 2023 & 2030 2.2 Medication for Recurrent Respiratory Infections Segment by Type 2.2.1 Immune System Products 2.2.2 Chemical Synthetic Agents 2.2.3 Biological Agents 2.2.4 Other 2.3 Medication for Recurrent Respiratory Infections Sales by Type 2.3.1 Global Medication for Recurrent Respiratory Infections Sales Market Share by Type (2019-2024) 2.3.2 Global Medication for Recurrent Respiratory Infections Revenue and Market Share by Type (2019-2024) 2.3.3 Global Medication for Recurrent Respiratory Infections Sale Price by Type (2019-2024) 2.4 Medication for Recurrent Respiratory Infections Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Other 2.5 Medication for Recurrent Respiratory Infections Sales by Application 2.5.1 Global Medication for Recurrent Respiratory Infections Sale Market Share by Application (2019-2024) 2.5.2 Global Medication for Recurrent Respiratory Infections Revenue and Market Share by Application (2019-2024) 2.5.3 Global Medication for Recurrent Respiratory Infections Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Medication for Recurrent Respiratory Infections Breakdown Data by Company 3.1.1 Global Medication for Recurrent Respiratory Infections Annual Sales by Company (2019-2024) 3.1.2 Global Medication for Recurrent Respiratory Infections Sales Market Share by Company (2019-2024) 3.2 Global Medication for Recurrent Respiratory Infections Annual Revenue by Company (2019-2024) 3.2.1 Global Medication for Recurrent Respiratory Infections Revenue by Company (2019-2024) 3.2.2 Global Medication for Recurrent Respiratory Infections Revenue Market Share by Company (2019-2024) 3.3 Global Medication for Recurrent Respiratory Infections Sale Price by Company 3.4 Key Manufacturers Medication for Recurrent Respiratory Infections Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Medication for Recurrent Respiratory Infections Product Location Distribution 3.4.2 Players Medication for Recurrent Respiratory Infections Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Medication for Recurrent Respiratory Infections by Geographic Region 4.1 World Historic Medication for Recurrent Respiratory Infections Market Size by Geographic Region (2019-2024) 4.1.1 Global Medication for Recurrent Respiratory Infections Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Medication for Recurrent Respiratory Infections Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Medication for Recurrent Respiratory Infections Market Size by Country/Region (2019-2024) 4.2.1 Global Medication for Recurrent Respiratory Infections Annual Sales by Country/Region (2019-2024) 4.2.2 Global Medication for Recurrent Respiratory Infections Annual Revenue by Country/Region (2019-2024) 4.3 Americas Medication for Recurrent Respiratory Infections Sales Growth 4.4 APAC Medication for Recurrent Respiratory Infections Sales Growth 4.5 Europe Medication for Recurrent Respiratory Infections Sales Growth 4.6 Middle East & Africa Medication for Recurrent Respiratory Infections Sales Growth 5 Americas 5.1 Americas Medication for Recurrent Respiratory Infections Sales by Country 5.1.1 Americas Medication for Recurrent Respiratory Infections Sales by Country (2019-2024) 5.1.2 Americas Medication for Recurrent Respiratory Infections Revenue by Country (2019-2024) 5.2 Americas Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 5.3 Americas Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Medication for Recurrent Respiratory Infections Sales by Region 6.1.1 APAC Medication for Recurrent Respiratory Infections Sales by Region (2019-2024) 6.1.2 APAC Medication for Recurrent Respiratory Infections Revenue by Region (2019-2024) 6.2 APAC Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 6.3 APAC Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Medication for Recurrent Respiratory Infections by Country 7.1.1 Europe Medication for Recurrent Respiratory Infections Sales by Country (2019-2024) 7.1.2 Europe Medication for Recurrent Respiratory Infections Revenue by Country (2019-2024) 7.2 Europe Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 7.3 Europe Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Medication for Recurrent Respiratory Infections by Country 8.1.1 Middle East & Africa Medication for Recurrent Respiratory Infections Sales by Country (2019-2024) 8.1.2 Middle East & Africa Medication for Recurrent Respiratory Infections Revenue by Country (2019-2024) 8.2 Middle East & Africa Medication for Recurrent Respiratory Infections Sales by Type (2019-2024) 8.3 Middle East & Africa Medication for Recurrent Respiratory Infections Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Medication for Recurrent Respiratory Infections 10.3 Manufacturing Process Analysis of Medication for Recurrent Respiratory Infections 10.4 Industry Chain Structure of Medication for Recurrent Respiratory Infections 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Medication for Recurrent Respiratory Infections Distributors 11.3 Medication for Recurrent Respiratory Infections Customer 12 World Forecast Review for Medication for Recurrent Respiratory Infections by Geographic Region 12.1 Global Medication for Recurrent Respiratory Infections Market Size Forecast by Region 12.1.1 Global Medication for Recurrent Respiratory Infections Forecast by Region (2025-2030) 12.1.2 Global Medication for Recurrent Respiratory Infections Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Medication for Recurrent Respiratory Infections Forecast by Type (2025-2030) 12.7 Global Medication for Recurrent Respiratory Infections Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 Roche 13.1.1 Roche Company Information 13.1.2 Roche Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.1.3 Roche Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Roche Main Business Overview 13.1.5 Roche Latest Developments 13.2 Anko Bio 13.2.1 Anko Bio Company Information 13.2.2 Anko Bio Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.2.3 Anko Bio Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Anko Bio Main Business Overview 13.2.5 Anko Bio Latest Developments 13.3 Bayer 13.3.1 Bayer Company Information 13.3.2 Bayer Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.3.3 Bayer Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Bayer Main Business Overview 13.3.5 Bayer Latest Developments 13.4 Merck & Co 13.4.1 Merck & Co Company Information 13.4.2 Merck & Co Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.4.3 Merck & Co Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Merck & Co Main Business Overview 13.4.5 Merck & Co Latest Developments 13.5 Sangene 13.5.1 Sangene Company Information 13.5.2 Sangene Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.5.3 Sangene Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 Sangene Main Business Overview 13.5.5 Sangene Latest Developments 13.6 Kain Technology 13.6.1 Kain Technology Company Information 13.6.2 Kain Technology Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.6.3 Kain Technology Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Kain Technology Main Business Overview 13.6.5 Kain Technology Latest Developments 13.7 Sinovac Pharmaceuticals 13.7.1 Sinovac Pharmaceuticals Company Information 13.7.2 Sinovac Pharmaceuticals Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.7.3 Sinovac Pharmaceuticals Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Sinovac Pharmaceuticals Main Business Overview 13.7.5 Sinovac Pharmaceuticals Latest Developments 13.8 Novartis 13.8.1 Novartis Company Information 13.8.2 Novartis Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.8.3 Novartis Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Novartis Main Business Overview 13.8.5 Novartis Latest Developments 13.9 Biogen 13.9.1 Biogen Company Information 13.9.2 Biogen Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.9.3 Biogen Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 Biogen Main Business Overview 13.9.5 Biogen Latest Developments 13.10 Merck KGaA 13.10.1 Merck KGaA Company Information 13.10.2 Merck KGaA Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.10.3 Merck KGaA Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Merck KGaA Main Business Overview 13.10.5 Merck KGaA Latest Developments 13.11 Zydus Cadila 13.11.1 Zydus Cadila Company Information 13.11.2 Zydus Cadila Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.11.3 Zydus Cadila Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Zydus Cadila Main Business Overview 13.11.5 Zydus Cadila Latest Developments 13.12 Huaxin Bio 13.12.1 Huaxin Bio Company Information 13.12.2 Huaxin Bio Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.12.3 Huaxin Bio Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 Huaxin Bio Main Business Overview 13.12.5 Huaxin Bio Latest Developments 13.13 Harbin Pharmaceutical Group 13.13.1 Harbin Pharmaceutical Group Company Information 13.13.2 Harbin Pharmaceutical Group Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.13.3 Harbin Pharmaceutical Group Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 Harbin Pharmaceutical Group Main Business Overview 13.13.5 Harbin Pharmaceutical Group Latest Developments 13.14 Xiamen Tebao 13.14.1 Xiamen Tebao Company Information 13.14.2 Xiamen Tebao Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.14.3 Xiamen Tebao Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 Xiamen Tebao Main Business Overview 13.14.5 Xiamen Tebao Latest Developments 13.15 AdvaCare Pharma 13.15.1 AdvaCare Pharma Company Information 13.15.2 AdvaCare Pharma Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.15.3 AdvaCare Pharma Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 AdvaCare Pharma Main Business Overview 13.15.5 AdvaCare Pharma Latest Developments 13.16 Connote Healthcare 13.16.1 Connote Healthcare Company Information 13.16.2 Connote Healthcare Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.16.3 Connote Healthcare Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Connote Healthcare Main Business Overview 13.16.5 Connote Healthcare Latest Developments 13.17 Glowderma Lab 13.17.1 Glowderma Lab Company Information 13.17.2 Glowderma Lab Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.17.3 Glowderma Lab Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Glowderma Lab Main Business Overview 13.17.5 Glowderma Lab Latest Developments 13.18 Janssen Pharmaceuticals 13.18.1 Janssen Pharmaceuticals Company Information 13.18.2 Janssen Pharmaceuticals Medication for Recurrent Respiratory Infections Product Portfolios and Specifications 13.18.3 Janssen Pharmaceuticals Medication for Recurrent Respiratory Infections Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Janssen Pharmaceuticals Main Business Overview 13.18.5 Janssen Pharmaceuticals Latest Developments 14 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医薬)の最新刊レポート
LP Information社の医薬品・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(medication)の最新刊レポート
よくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/23 10:26 157.72 円 164.94 円 201.11 円 |